Drug Trial Radar · NCT07949981
Celiac Versus Splanchnic Neurolysis in Abdominal Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Mar 15, 2026
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Pain Medicine DepartmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the analgesic efficacy, patient quality of life and safety profile of celiac plexus neurolysis versus splanchnic neurolysis in patients of abdominal malignancies. Sixty patients suffering from abdominal malignancies. Patients in Group C were administered celiac plexus neurolysis while those in Group S were administered bilateral splanchnic neurolysis. The primary outcome was the pain score measured by the Visual analogue score at two, four and eight and twelve weeks following the procedure. The secondary outcome was improvement in patient quality of life using SF12 questionnaire and safety profile of the procedure.
Conditions
- Abdominal Malignancy
Interventions
Celiac Plexus BlockDrug
Celiac plexus neurolysis
Splanchnic nerve blockDrug
Splanchnic Neurolysis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pain intensity on the Visual Analog Scale (VAS) from baselineTime frame: baseline (pre-procedure), and weeks 2, 4, 8, and 12 after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Combined military hospital
Lahore, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.